Inhibition of both Tie2 and CSF-1 signaling to prevent TAVO events, along with standard of care therapies, might be an effective way to prevent re-dissemination from both primary and metastatic tumor sites, and allow for better patient survival. The gene discussed is TEK; the disease is metastatic neoplasm.